Results 111 to 120 of about 2,262 (198)

Going Viral: An Investigation into the Chameleonic Behaviour of Antiviral Compounds. [PDF]

Chemistry, 2023
Wieske LHE, Atilaw Y, Poongavanam V, Erdélyi M, Kihlberg J.   +4 more
europepmc   +1 more source

Safety Exposure‐Response Analysis for Daclatasvir, Asunaprevir, and Beclabuvir Combinations in HCV‐Infected Subjects

, 2018
Mayu Osawa, Takayo Ueno, Tomomi Shiozaki, Hanbin Li, Tushar S. Garimella   +4 more
openalex   +1 more source

Evaluating long-term outcomes of direct-acting antiviral therapy in chronic hepatitis C: A retrospective study. [PDF]

Medicine (Baltimore)
Sung BR, Shim SG, Kim KM, Lee JW, Kim JY, Lee BK, Jun CH, Kwan BS.   +7 more
europepmc   +1 more source

Are Direct-Acting Antivirals Effective and Safe for Hepatitis C Patients with Arterial Hypertension? Evidence from a Large Retrospective Real-World Study. [PDF]

Viruses
Brzdęk M, Rzymski P, Zarębska-Michaluk D, Poniedziałek B, Lorenc B, Berak H, Mazur W, Janocha-Litwin J, Tudrujek-Zdunek M, Sitko M, Klapaczyński J, Flisiak R.   +11 more
europepmc   +1 more source

IKAROS levels are associated with antigen escape in CD19- and CD22-targeted therapies for B-cell malignancies. [PDF]

Nat Commun
Domizi P, Sarno J, Jager A, Merchant M, Pacheco KZB, Yamada-Hunter SA, Rotiroti MC, Liu Y, Baskar R, Reynolds WD, Sworder BJ, Sahaf B, Bendall SC, Mullighan CG, Alizadeh AA, Leahy AB, Myers RM, Yates B, Wang HW, Shah NN, Majzner RG, Mackall CL, Mackall CL, Grupp SA, Barrett DM, Sotillo E, Davis KL.   +26 more
europepmc   +1 more source

Efficacy and Safety of Daclatasvir and Asunaprevir Combination Therapy in Elderly Chronic Hepatitis C Patients

, 2018
박유경, 강진숙, 최유옥, 최혜정, 황보신이, 신수진   +5 more
openalex   +1 more source

Succesful treatment of chronic hepatitis C virus infection with daclatasvir and asunaprevir in a transfusion dependent thalassaemia patient

, 2016
Thalassaemia is one of the most common inherited hemoglobinopathies that is characterized with defective hemoglobin synthesis and ineffective erythropoiesis. Chronic transfusion therapy which increases the risk of hepatitis C virus (HCV) infection is the
ÖZTÜRK, ÖMER, KÖKLÜ, SEYFETTİN, Aksoy, Evrim Kahramanoglu, Tseveldorj, Nomingerel, KÖKLÜ, HAYRETDİN   +4 more
core  

Modeling predicts shortening of DAA treatment duration to 5 weeks in individuals with recent or chronic infection with HCV RNA negativity at day 7 on treatment. [PDF]

J Infect Dis
Goyal A, Cotler SJ, Matthews GV, Page K, Kushner T, Etzion O, Martinello M, Dahari H.   +7 more
europepmc   +1 more source

Interaction of immunosuppressants with HCV antivirals daclatasvir and asunaprevir: combined effects with mycophenolic acid

, 2018
Petra E. de Ruiter, Yashna Gadjradj, Robert Jacobus de Knegt, Herold Johnny Metselaar, Jan N.M. IJzermans, Luc J. W. van der Laan   +5 more
openalex   +2 more sources

The efficacy and safety of direct-acting antiviral regimens for end-stage renal disease patients with HCV infection: a systematic review and network meta-analysis. [PDF]

Front Public Health, 2023
Chen R, Xiong Y, Zeng Y, Wang X, Xiao Y, Zheng Y.   +5 more
europepmc   +1 more source